Stockreport

Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade) [Seeking Alpha]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF YARTEMLEA's U.S. peak annual sales are estimated at no more than $250 million, given the niche, fragmented TA-TMA market and entrenched off-label competition. The Nov [Read more]